HematologyNews.net

Hematology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Kyprolis for the treatment of patients with multiple myeloma who have received at least two prior therapies including Bortezomib and an immunomodulatory agent


The Food and Drug Administration ( FDA ) has granted accelerated approval of Kyprolis ( Carfilzomib ) for injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including Bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
The indication for Kyprolis is based on response rate. Currently, no data are available for Kyprolis that demonstrate an improvement in progression-free survival or overall survival.

The approval was based on the results of the Phase 2b 003-A1 study, a single-arm, multicenter clinical trial that enrolled 266 patients with multiple myeloma who had received a median of five prior anti-myeloma regimens.
The primary efficacy endpoint was overall response ( ORR ) and determined by an Independent Review Committee using the International Myeloma Working Group ( IMWG ) criteria.
ORR was 22.9% and median response duration was 7.8 months.

Safety data were evaluated in 526 patients with relapsed and/or refractory multiple myeloma who received single-agent Carfilzomib. There were 37 deaths on study, or 7% of patients. The most common causes of death, other than disease progression, were cardiac ( 5 patients ), end-organ failure ( 4 patients ), and infection ( 4 patients ).

Important warnings and precautions include cardiac arrest, congestive heart failure, myocardial ischemia; pulmonary hypertension, pulmonary complications, infusion reactions, infusion reactions, tumor lysis syndrome, thrombocytopenia, hepatic toxicity and embryo-fetal toxicity.

The most common serious adverse reactions were pneumonia, acute renal failure, pyrexia, and congestive heart failure.
The most common adverse reactions ( incidence of 30% or greater ) observed in clinical trials of patients with multiple myeloma were fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and pyrexia. Serious adverse reactions were reported in 45% of patients.

Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In the United States, more than 50,000 people are living with multiple myeloma and approximately 20,000 new cases are diagnosed annually. Worldwide, more than 220,000 people are living with multiple myeloma and approximately 100,000 new cases are diagnosed annually. ( Xagena )

Source: Onyx, 2012

XagenaMedicine_2012



Indietro